Lorazepam Articles
"1,000%+ pharmacy mark up" on generics
8 January 2009
Headlines 25 years ago this week....
1 October 2007
Amarin licenses nasal lorazepam from Elan
12 March 2007
US FDA warns about misrepresented drugs bought over the Internet
26 February 2007
Mylan adjusts EPS forecast
18 July 2005
Second FDA drug imports "blitz" finds 80% come from Canada
9 February 2004
Biovail in $130M rights deal with Wyeth
9 June 2003
Mylan gets $22.5M in Aventis settlement
21 April 2003
Baxter acquires ESI in $305M deal
6 January 2003
Mylan pays $2.1M to victims of scandal
8 July 2002
Brazil approves purchase of Ranbaxy's generic lorazepam
14 August 2001
Faulding sales rise 17.5%, boosted by pharma
9 August 2001
Refunds for consumers from US antitrust deal?
1 June 2001
Michigan in generic price-fixing lawsuit
12 February 1999
Schwarz Pharma buys Italian rights to Lorans
29 December 1998
FTC charges Mylan et al of overpricing
24 December 1998
Mylan Responds To FTC Charges
18 December 1998
Stock Commentary New York
17 December 1998
US FTC Widens Probe On Generic Prices
28 July 1998
FTC Subpoenas Mylan In Generics Investigation
24 July 1998
Mylan In Generics Prices Row
15 July 1998
US Probe Sought On Generic Drug Prices
11 March 1998
Greek Govt Adjusts Prices Of 6,009 Drugs
3 October 1997
US FDA APPROVES NEW GENERICS
16 May 1994
STERLING WINTHROP GENERICS ARM
25 April 1994
ANANXYL WITHDRAWN FROM MARKET IN FRANCE
1 November 1993
AMERICAN HOME HAS CONFIDENCE FOR 1993
12 April 1993
WORLD CNS MARKET IS LARGE AND FRAGMENTED
22 February 1993
BENZODIAZEPINE LITIGATION
1 February 1993
POST-ELECTION OUTLOOK FOR UK HEALTH SECTOR
20 April 1992
Showing 1-34 of 34 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
